Context Therapeutics Inc. (NASDAQ:CNTX) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Context Therapeutics Inc. (NASDAQ:CNTX) have been assigned a consensus rating of “Moderate Buy” from the ten analysts that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $6.1667.

Several brokerages have recently commented on CNTX. Citigroup reaffirmed an “outperform” rating on shares of Context Therapeutics in a research report on Thursday, August 6th. Weiss Ratings raised Context Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday. Lifesci Capital lowered Context Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. Maxim Group decreased their price objective on Context Therapeutics from $8.00 to $4.00 and set a “buy” rating for the company in a research report on Tuesday, June 16th. Finally, Wall Street Zen cut Context Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Monday, July 20th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CNTX. Vanguard Group Inc. increased its stake in Context Therapeutics by 4.0% in the 3rd quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock valued at $3,387,000 after buying an additional 134,449 shares during the period. Citadel Advisors LLC purchased a new stake in Context Therapeutics in the 3rd quarter worth approximately $100,000. Blue Owl Capital Holdings LP boosted its stake in shares of Context Therapeutics by 0.3% during the 4th quarter. Blue Owl Capital Holdings LP now owns 7,432,906 shares of the company’s stock valued at $10,926,000 after buying an additional 25,000 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Context Therapeutics by 58.8% during the 4th quarter. Renaissance Technologies LLC now owns 508,329 shares of the company’s stock valued at $747,000 after buying an additional 188,202 shares during the period. Finally, State Street Corp grew its holdings in shares of Context Therapeutics by 8.5% during the 4th quarter. State Street Corp now owns 165,607 shares of the company’s stock valued at $243,000 after acquiring an additional 13,000 shares in the last quarter. 14.03% of the stock is owned by hedge funds and other institutional investors.

Context Therapeutics Stock Performance

Shares of NASDAQ:CNTX opened at $0.47 on Tuesday. The firm has a 50 day simple moving average of $0.59 and a 200 day simple moving average of $1.79. Context Therapeutics has a 52 week low of $0.43 and a 52 week high of $3.62. The company has a market cap of $42.76 million, a PE ratio of -0.97 and a beta of 1.74.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.06). On average, equities analysts predict that Context Therapeutics will post -0.4 earnings per share for the current year.

About Context Therapeutics

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.